Half-year report · Q2

Period2025-01-01 → 2025-06-30
Filed2025-08-12
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales (5-year summary)
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet income loss (5-year summary)
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Total assets¥2.0bnat 2025-06-30StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.6bnat 2024-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥443mat 2025-06-30StandaloneLiabilities
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.5bnat 2025-06-30StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 427
ItemContextValueUnit
Independent auditors report non consolidated (text)FilingDateInstantText · Plus
Audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)太 陽 有 限 責 任 監 査 法 人
Cpa1 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)田 村  知 弘
Cpa2 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)櫻 井  純 一
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration_NonConsolidatedMember263728000JPY
Net sales (5-year summary)CurrentYTDDuration_NonConsolidatedMember251796000JPY
Net sales (5-year summary)Prior1YearDuration_NonConsolidatedMember780809000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration_NonConsolidatedMember-563345000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration_NonConsolidatedMember-539020000JPY
Ordinary income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-1019210000JPY
Net income loss (5-year summary)Prior1YTDDuration_NonConsolidatedMember-563958000JPY
Net income loss (5-year summary)CurrentYTDDuration_NonConsolidatedMember-540290000JPY
Net income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-1020776000JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YTDDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)CurrentYTDDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YearDuration_NonConsolidatedMember-JPY
Capital stock (5-year summary)Prior1QuarterInstant_NonConsolidatedMember341497000JPY
Capital stock (5-year summary)CurrentQuarterInstant_NonConsolidatedMember1065558000JPY
Capital stock (5-year summary)Prior1YearInstant_NonConsolidatedMember995525000JPY
Total number of issued shares (5-year summary)Prior1QuarterInstant_NonConsolidatedMember56387000
Total number of issued shares (5-year summary)CurrentQuarterInstant_NonConsolidatedMember68053800
Total number of issued shares (5-year summary)Prior1YearInstant_NonConsolidatedMember66969000
Net assets (5-year summary)Prior1QuarterInstant_NonConsolidatedMember1070531000JPY
Net assets (5-year summary)CurrentQuarterInstant_NonConsolidatedMember1519330000JPY
Net assets (5-year summary)Prior1YearInstant_NonConsolidatedMember1920303000JPY
Total assets (5-year summary)Prior1QuarterInstant_NonConsolidatedMember1557439000JPY
Total assets (5-year summary)CurrentQuarterInstant_NonConsolidatedMember1962725000JPY
Total assets (5-year summary)Prior1YearInstant_NonConsolidatedMember2468857000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-10.21
Basic earnings loss per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-7.97
Basic earnings loss per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-17.54
Diluted earnings per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Equity to asset ratio (5-year summary)Prior1QuarterInstant_NonConsolidatedMember0.680
Equity to asset ratio (5-year summary)CurrentQuarterInstant_NonConsolidatedMember0.769
Equity to asset ratio (5-year summary)Prior1YearInstant_NonConsolidatedMember0.774
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration_NonConsolidatedMember-677388000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration_NonConsolidatedMember-673006000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration_NonConsolidatedMember-1000695000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration_NonConsolidatedMember-JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration_NonConsolidatedMember-JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember-JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration_NonConsolidatedMember455490000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration_NonConsolidatedMember84678000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember1738421000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-06-30pass